All News
Filter News
Found 132 articles
-
Soligenix Corporate Update Letter - Key Highlights and Upcoming Catalysts
1/10/2022
Soligenix, Inc. today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.
-
Movers & Shakers, Jan. 7
1/7/2022
With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers. -
Galera to Present at H.C. Wainwright BioConnect Conference
1/6/2022
Galera Therapeutics, Inc. announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, taking place January 10-13, 2022.
-
Context Therapeutics® Strengthens Research & Development Team
1/5/2022
Context Therapeutics Inc., a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, announced the appointments of Christopher Beck as SVP of Operations and Mark Fletcher, Ph.D., as VP of R&D.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
ImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, "Cold" Cancers
12/14/2021
ImmunoGenesis announced the appointment of seasoned industry veteran Charles Schweizer , PhD, as Senior Vice President of Clinical Development.
-
Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem
12/14/2021
Galera Therapeutics, Inc. (Nasdaq: GRTX), today announced that corrected results from its Phase 3 ROMAN trial of avasopasem for the treatment of RT-induced severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) achieved statistical significance on the primary endpoint of reduction in the incidence of SOM.
-
Innovation Pharmaceuticals Provides Brilacidin Program Update
11/18/2021
Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, provided an update on clinical development plans for Brilacidin, the Company's defensin-mimetic drug candidate being evaluated in clinical testing for multiple indications.
-
Galera to Present at Two Upcoming Investor Conferences in November 2021
11/15/2021
Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at two upcoming investor conferences in November.
-
Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
11/10/2021
Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, announced financial results for the third quarter ended September 30, 2021 and provided recent corporate updates.
-
Clinical Catch-Up: October 18-22
10/25/2021
It was yet another busy week for clinical trial news. Here’s a look. -
Biopharma News You've Missed This Week
10/20/2021
More than $170 million was paid out for drugs that manufacturers voluntarily withdrew from the market after subsequent trials showed no benefit in overall survival. -
Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis
10/19/2021
Galera Therapeutics, Inc. (Nasdaq: GRTX), today announced results from the Phase 3 ROMAN trial of avasopasem manganese (avasopasem) for severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) undergoing standard-of-care radiotherapy.
-
BioSpace Movers & Shakers, Oct. 15
10/15/2021
Biopharma and life sciences companies strengthen their leadership teams and executive boards with these Movers & Shakers. -
Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer
10/12/2021
Galera Therapeutics, Inc. announced the appointment of Mark J. Bachleda, Pharm.D., M.B.A., as Chief Commercial Officer and Jennifer Evans Stacey, Esq., as Chief Legal and Compliance Officer and Secretary.
-
Nanocan Therapeutics Corporation Appoints Renowned Oncologist Dr. Elizabeth Charlotte Moser as Chief Scientific Officer
9/28/2021
Nanocan Therapeutics Corporation (Nanocan), a clinical stage biotechnology company developing innovative cancer treatments, announced the appointment of Dr. Elizabeth Charlotte Moser, as its Chief Scientific Officer and member of the company's executive leadership team.
-
Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer
9/14/2021
Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, announced that the Company will host a virtual Key Opinion Leader event on radiotherapy-induced severe oral mucositis in patients with head and neck cancer on Thursday, September 23 at 11:00 a.m. ET.
-
Clinical Catch-Up: September 6-10
9/13/2021
It was a very busy week for clinical trial announcements, although there were only three that were COVID-19-related. Here’s a look. -
Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters
9/8/2021
Galera Therapeutics, Inc. announced final results from its Phase 1/2 pilot trial of its dismutase mimetic, GC4419, versus placebo, in patients with unresectable or borderline resectable locally advanced pancreatic cancer, who are undergoing stereotactic body radiation therapy.
-
Galera to Present at Three Upcoming Investor Conferences in September 2021
9/7/2021
Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at three upcoming virtual investor conferences in September.